Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
Official title: Project 2: Multimodal AI-based outcomes prediction in stage III NSCLC
Funded at Emory University · NIH-11422847 · Data updated 2026-11-12
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | August 18, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $412,567 |
| NIH project number | 1P50CA302567-01A1 |
| Project ID | NIH-11422847 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with unresectable stage III NSCLC who have completed concurrent CRT and are candidates for consolidation durvalumab, with sufficient performance status.
✕Less likely to help
Patients not receiving durvalumab after CRT or those with contraindications to immunotherapy may not benefit from these predictions.
What this research studies
This project combines advanced imaging and artificial intelligence to create prognostic and predictive tests for people with locally advanced, unresectable NSCLC treated with CRT followed by durvalumab. It analyzes radio-pathomic features from CT scans and tumor tissue images, aiming to predict treatment response and survival, as well as the risk of pneumonitis. A secondary goal is to relate these imaging signatures to ctDNA dynamics, potentially guiding future treatment decisions. The work seeks to translate complex imaging biomarkers into actionable tools that clinicians can use to tailor therapy for NSCLC patients. The study is designed to integrate findings into clinical workflows to improve personalized care.
Why it matters
Potential benefit: Patients could receive more personalized treatment plans and potentially reduced risk of severe side effects like pneumonitis.
How similar studies have gone: Past work shows promise for imaging-based biomarkers predicting immunotherapy response, but this exact radio-pathomic approach in this context is exploratory and building on early signals.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Madabhushi, Anant — Emory University
- Study coordinator: Madabhushi, Anant
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
-
Delta immune ecology of NSCLC in KRAS-mutant cancers
A study in people with NSCLC (especially KRAS-mutant) will examine how immune cells and tumor interactions change during treatment and how this could guide better therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.